Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Tucidinostat Plus Etoposide in the Treatment of Relapsed or Refractory Neuroblastoma in Children

NCT05338541 is registered in ClinicalTrials.gov with Yizhuo Zhang as lead sponsor.

NCT NCT05338541
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05338541 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Tucidinostat Plus Etoposide in the Treatment of Relapsed or Refractory Neuroblastoma in Children
Lead sponsor
Yizhuo Zhang
Phase
Phase 1
Overall status
Unknown status
Start date
May 27, 2022
Completion date
December 31, 2024
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

neuroblastoma in children